Kornimate/medical-research-clean huggingface dataset:
utility of laboratory testing for children with seizure in emergency department

Conditions: Seizure

Summary: objective: to evaluate the predisposing factors associated with abnormal laboratory findings in patients who came to the emergency room due to a first seizure. methods: patients were divided into separate groups based on normal and abnormal laboratory results for sodium, potassium, calcium, and glucose. the difference in age, gender, whether this was the first attack, whether there was fever, whether there were gastrointestinal symptoms, the duration and pattern of the seizure, and whether there was a seizure at the emergency department, were evaluated.


Eligibility criteria:
inclusion criteria: * age: less than 18 years old * the patient came to emergency department due to seizure * the patient received blood sampling including serum sodium, potassium, calcium and glucose. exclusion criteria: * the patient came to the outpatient department. * the patient did not received blood sampling at emergency room. * the seizure occurred after admission.

Keywords: seizure electrolyte risk factor
behavioral treatment for substance abuse

Conditions: Substance-Related Disorders

Summary: this pilot project will evaluate a new mind-body intervention called mind-body bridging (mbb) for reducing substance abuse problems in women who are undergoing a substance abuse treatment program. the main hypothesis is that mbb will be more effective than the control (standard) intervention program in helping people reduce their craving for illicit substances and/or alcohol.

this is a randomized clinical pilot study in which mbb will be compared with a standard treatment program for substance abuse. both groups will run concurrently over the course of a 10-week period, twice per week.

Eligibility criteria:
inclusion criteria: * substance abuse or dependence * resident/day client in the house of hope substance abuse treatment program * minimum stay in treatment at house of hope for 3.5 months * fluent in english exclusion criteria: * psychosis * suicide risk * dementia * significant withdrawal risk * severe, unstable depression * requires intensive mental health treatment * cognitive impairment

Keywords: substance abuse substance addiction substance dependence treatment program
a study to find the best doses of su011248 and gemcitabine when given together to patients with advanced solid tumors

Conditions: Solid Tumors

Summary: this study assesses the maximum tolerated dose, overall safety and antitumor activity of su011248 in combination with gemcitabine in patients with advanced solid tumors


Eligibility criteria:
inclusion criteria: * patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists * patient has good performance status (ecog 0 or 1) exclusion criteria: * prior treatment with either gemcitabine or su011248 * hypertension that cannot be controlled by medications

Keywords: solid tumor malignancy, su011248, sunitinib, neoplasms
screening for gynecologic cancers in hereditary nonpolyposis colorectal cancer (hnpcc) patients

Conditions: Colon Cancer

Summary: among women with hnpcc, this study will assess: 1. knowledge of screening recommendations for endometrial and ovarian cancers. 2. perceived risk and cancer worries regarding endometrial, ovarian and colorectal cancers. 3. adherence to screening recommendations for endometrial, ovarian and colon cancers. 4. perceived benefits,supports and barriers to endometrial and ovarian cancer screening. 5. patterns of communication about endometrial and ovarian cancer risk within families with hnpcc and with health care providers. 6. patient preferences for potential cancer screening and cancer prevention strategies related to hnpcc-associated cancers.

women who are at risk for hnpcc will be recruited to participate in this pilot study. women will be invited to participate in the study either through a mailed invitation or during a visit to m.d. anderson for clinical services or for research purposes. women who wish to participate in the study will complete an informed consent, and will subsequently schedule an appointment with a research coordinator to complete the study questionnaire by telephone.

Eligibility criteria:
inclusion criteria: 1. being female 2. being 25 years of age or older 3. having an hnpcc-predisposing mutation and/or having a family history of cancer that meets the amsterdam or amsterdam ii criteria for hnpcc exclusion criteria: 1. persons who have tested negative for a known hnpcc-predisposing mutation in their family 2. persons who have no family hnpcc mutation and have not met the amsterdam i/ii criteria 3. being younger than 25 years old 4. note: women who have had a prior history of colorectal cancer or polyps will not be excluded unless they meet one of the above exclusion criteria.

Keywords: hereditary non-polyposis colon cancer gynecologic cancers genetic counseling questionnaire survey hnpcc
colorectal metastasis to liver extraction with auxiliary transplant and delayed resection

Conditions: Liver Transplant Surgery; Colorectal Cancer Metastatic; Colon Cancer Liver Metastases

Summary: liver transplantation (lt) has become an accepted treatment for selected patients with unresectable liver metastases due to colorectal cancer (crlm). the goal of this study is to look at and compare the clinical results of all the different approved methods (living vs. deceased, whole organ vs. split, one staged vs. two staged) used to perform a standard liver transplant procedure for recipients with crlm. investigators will look at things like different procedure results, recovery in the hospital, and survival rates one year after the transplant. investigators will also take blood samples from participants to be used in future research. all the transplant methods the investigators are comparing are standard practices approved by the united network of organ sharing (unos).


Eligibility criteria:
inclusion: 1. all patients of either gender ≥ 18 years of age who are listed for liver transplant candidates at northwestern with liver metastases due to colorectal cancer (crlm). 2. subjects must be able to provide informed consent themselves and without the use of a legally authorized representative (lar), to be determined by the pi or sub-i at the time of consent. exclusion: 1. adults unable to consent 2. pregnant women 3. certain clinical/surgical/anatomical parameters, at the discretion of the pi.

Keywords: liver transplant colorectal cancer metastatic colorectal cancer
an observational study to assess participant-reported real-world experience of risankizumab on-body injector (obi) for the treatment of crohn's disease in adult participants in the united kingdom (uk)

Conditions: Crohn's Disease

Summary: crohn's disease (cd) is a chronic condition that causes inflammation of the gastrointestinal tract or gut. this study will assess real-world, adult participant experience of self-injection with the risankizumab obi. risankizumab is an approved drug for the treatment of cd in adults. approximately 80 participants who are prescribed risankizumab by their doctors and are transitioning from the pre-filled syringe (pfs) to the use of obi will be enrolled in this study in the united kingdom (uk). participants will receive risankizumab obi as prescribed by their physician according to their routine clinical practice and local label. participants will be followed for up to 6 months. there is expected to be no additional burden for participants in this trial. study visits may be conducted on-site, at home, or virtually as per standard of care.


Eligibility criteria:
inclusion criteria: * aged 18 years or older * eligible for and received risankizumab for maintenance treatment of crohn's disease (cd) through united kingdom (uk) early access to medicines scheme (eams)/pre-approval access (paa) schemes * the decision to treat with risankizumab was made independently, in line with usual clinical practice, marketing authorisation and prior to enrolment in the study * exits uk eams/paa and switches from risankizumab pre-filled syringe (pfs) to on-body injector (obi) * can physically self-administer risankizumab obi without carer assistance * can read and understand english * willing and able to provide voluntary informed consent * able and willing to participate in this study. exclusion criteria: n/a

Keywords: crohn's disease risankizumab skyrizi
effects of probiotics on neonatal hyperbilirubinemia

Conditions: Neonatal Hyperbilirubinemia

Summary: this study was designed as a prospective controlled study to investigate the effects of probiotic support started immediately after birth on newborn jaundice in breastfed babies born by normal spontaneous vaginal delivery.

objectives: enterohepatic circulation of bilirubin imposes an extra burden of approximately 30% on total serum bilirubin levels. intestinal microflora is the main factor affecting enterohepatic circulation. this study investigated the effects of probiotic support started immediately after birth on neonatal hyperbilirubinemia in babies born by normal spontaneous vaginal delivery and breastfed only. methods: a total of 150 healthy term newborns were included in the study and allocated in the study and control groups. immediately after birth, newborns in the study group received probiotic in liquid drop form (maflor® drops containing lactobacillus rhamnosus gg 109 colony forming units(cfu), mamsel pharmaceuticals, turkey), at a dose of 5 drops a day orally for 10 days. newborns in the control group received 5 drops of saline solution per day orally, instead. in addition to routine biochemical examinations;serum bilirubin levels in the cord blood, and blood samples of the newborns on the 3rd, 5th and 10th days of birth were measured in all subjects in both groups. defecation frequency was recorded for all subjects.

Eligibility criteria:
inclusion criteria: * a total of 150 full-term (gestational age ≥37 - \<42 weeks) normal spontaneous vaginal delivery healthy newborns * birth weight between the 10th-90th percentiles * fed by breast milk only exclusion criteria: * newborns with familial hematologic disorders * having signs of hemolysis due to blood group incompatibilities * bleeding into closed spaces due to birth trauma complications (e.g. cephalohematoma) * suspected or documented neonatal infection such as chorioamnionitis, intrauterine infection, sepsis and urinary tract infection * perinatal and neonatal hypoxia * having thyroid dysfunction, respiratory distress or insufficiency, metabolic and thermoregulatory dysfunction, hemodynamic instability and congenital heart disease * maternal phenobarbital usage history during the last month of the pregnancy * having venous hematocrit (htc) levels≥65%

Keywords: probiotic neonatal hyperbilirubinemia
the effects of acute administration of bupropion on neural substrates underlying hedonic capacity

Conditions: Major Depressive Disorder

Summary: the purpose of the study is to evaluate the effects of a single-dose of wellbutrin xl (bupropion hydrochloride) on reward processing.

a cardinal feature of major depressive disorder is anhedonia, which is a lack of pleasure in normally enjoyable activities. in order to understand reward processing in depressed individuals it is also necessary to study reward processing in people who are not depressed. bupropion, the active drug in the anti-depressant wellbutrin xl, has been shown to increase brain reward functioning in animals. the goal of the present study is to investigate the effects of wellbutrin xl administered to psychiatrically healthy individuals as they perform a computer task known to assess reward processing.

Eligibility criteria:
inclusion criteria: * absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse) * non-smoker * right-handed (chapman and chapman 1987) * ability to provide informed consent exclusion criteria: * predisposition to seizure (e.g. family history of a seizure disorder, history of head trauma) or current use of medications that lower the seizure threshold * history or current diagnosis of anorexia or bulimia * alcohol or substance abuse within the past year * current usage of wellbutrin or zyban or other drugs that contain bupropion * recent discontinuation of alcohol or sedatives (including benzodiazepines) * use of (in the last 2 weeks) medications that may have antidepressant properties (ex. some herbal supplements) * known allergies to bupropion * currently lactating, pregnant or believe you are likely to be pregnant (enrolled subjects who are not using reliable contraception and have engaged in sexual intercourse since their last menstrual period will be given a self-administered pregnancy test.) * left-handed/ambidextrous * evidence of neurological illness * serious suicide or homicide risk concomitant medications other than those listed in the exclusion criteria will be considered on an individual basis. oral contraceptives will be allowed.

Keywords: reward processing wellbutrin bupropion
diabetic retinopathy tethered augmented reality with eye4 study

Conditions: Diabetic Retinopathy; Low Vision

Summary: diabetes has reached epidemic levels in north america and with it, diabetic retinopathy is increasingly affecting the vision of millions of people. despite treatment many patients still have vision loss that cannot be improved medically or with prescription eyeglasses. our study is going to look at an fda class 1 exempted visual aid that uses augmented reality to help people see better.

in this study subjects will have their best corrected visual acuity and contrast sensitivity compared to their best vision and contrast with the eyedaptic device. the eyedaptic device is an fda 510(k) class 1 exempt device as it is a visual aid. this is a pilot study to determine whether subjects with diabetic retinopathy associated vision loss obtain a benefit with augmented reality vision. subjects will receive a manifest refraction. when subjects have their optimal corrective lenses, the subjects' vision will be tested with their corrective lenses alone and again using the eyedaptic device. this will be a single visit study, with no follow up.

Eligibility criteria:
inclusion criteria: * best correct visual acuity in the better seeing eye between 20/60 and 20/800 * history of diabetic retinopathy exclusion criteria: * unable to complete the visit * unable to give a reliable measurement of vision * unable to comfortably wear the glasses for at least 60 minutes
treatment with copper in patients with mild alzheimer´s dementia

Conditions: Alzheimer´s Disease

Summary: the efficacy of 8 mg of copper daily regarding cognitive function, content of beta amyloid protein in the csf and volumetric changes in the brain will be examined in a first double-blind, placebo-controlled human clinical trial conducted in 70 patients with mild alzheimer´s dementia.


Eligibility criteria:
inclusion criteria: * male or female patients * between 50 and 80 years * criteria of mild dementia * probable alzheimer´s dementia according to nincds-adrda criteria * given written informed consent * having a relative who can fill out questionnaire; caregiver consent * free of serious and unstable somatic illness exclusion criteria: * unable to give informed consent * unable to take cholinesterase inhibitors * unapproved medication * moderate to severe alzheimer´s disease * dementia of other etiology * history of alcohol, drug or medication abuse * other psychiatric disorder, e. g. schizophrenia * known copper and zinc storage disease * known copper and zinc intolerance * vegans * known severe allergies or intolerances * insufficient knowledge of the german language * female patients of childbearing potential, pregnant or nursing patients * participation in a clinical trial within the past 30 days before onset of this study * severe somatic diseases and high mortality rate ast, alt, ggt, gldh, ap or bilirubin being a two-fold above the normal range

Keywords: efficacy of treatment with copper in patients with mild alzheimer´s disease cognitive status over time csf and volumetric data over time (1 year)
repeat study - a study of pegasys (peginterferon alfa-2a (40kd)) therapy in combination with copegus (ribavirin) in patients with chronic hepatitis c (chc) who did not respond to previous pegintron (peginterferon alfa-2b (12kd))/ribavirin combination therapy

Conditions: Hepatitis C, Chronic

Summary: this 4 arm study is designed for patients with chc who have not responded to peginterferon alfa-2b (12kd)/ribavirin combination therapy. in these patients, the effects of lengthening the duration of treatment, as well as including an initial 12-week period of high-dose pegasys (360 micrograms sc), are compared with the standard combination therapy of pegasys (180 micrograms sc) and ribavirin (1000-1200mg po). the anticipated time on study treatment is 1-2 years and the target sample size is 500+ individuals.


Eligibility criteria:
inclusion criteria: * adult patients \>=18 years of age; * chc infection; * liver biopsy (in \<24 calendar months of first dose), with results consistent with chc infection; * use of 2 forms of contraception during study and 6 months after the study in both men and women; * lack of response to previous treatment with peginterferon alfa-2b (12kd)/ribavirin combination therapy given for \>=12 weeks. exclusion criteria: * women who are pregnant or breastfeeding; * male partners of women who are pregnant; * conditions associated with decompensated liver disease; * other forms of liver disease, including liver cancer; * human immunodeficiency virus infection.
the effect of jincaopian tablets on chronic pelvic pain after pelvic inflammatory disease

Conditions: Chronic Pelvic Pain

Summary: this phase ii trial attempts to evaluate the efficacy and safety of jincaopian tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease.

chronic pelvic pain is the major sequela of pelvic inflammatory disease and it's a common, burdensome, and costly condition that disproportionately affects women. this multicenter, randomized, double-blind, dose-parallel, placebo-controlled phase ii clinical trial is designed to evaluate the efficacy and safety of jincaopian tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease. in this trial, 180 subjects were enrolled and randomized to either "high-dose jincaopian tablets" group, "low-dose jincaopian tablets " group, or the "placebo" group in a 1:1:1 ratio. the treatment period is 12 weeks and the follow-up period is 4 weeks. the outcome measures of chronic pelvic pain relief in this trial are pain visual analog scale (vas), modified mccormick scale and sf-12 score.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for chronic pelvic pain sequelae of pelvic inflammatory disease; * the average vas score of pain in the week before enrollment is ≥4; * the mccormack scale of physical signs at the time of enrollment is 4 to 12 points (including 4 points and 12 points); * women aged 18 to 55 (including 18 and 55) with a history of sexual life; * voluntarily participate in this clinical trial, give informed consent and sign the informed consent form. exclusion criteria: * pelvic inflammatory disease (acute attack); * pregnant or lactating women, women of childbearing age who are unwilling to take effective measures to prevent pregnancy during the trial and within 3 months after the trial; * critically ill or with surgical indications; * previously diagnosed with cervical intraepithelial neoplasia, primary/secondary dysmenorrhea, pelvic stasis syndrome and chronic pelvic pain caused by other non-pelvic inflammatory diseases; * complicated with specific vaginitis such as vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, etc.; * gynecological tumors (maximum diameter of uterine fibroids greater than 3cm and submucosal fibroids), endometriosis, adenomyosis, acute cervicitis, tuberculous pelvic inflammatory disease, interstitial cystitis and other diseases related symptoms; * placement of intrauterine device in the past 3 months; absence of uterus and bilateral appendages; * received related treatment or took drugs with similar functions and indications within 14 days before the introduction; * have a history of allergy to the components of the test drug; * participated in other clinical trials within the past 3 months; * the investigator believes that it is not suitable to participate in this clinical trial.
compound staphylococcal lysostaphin vs. chlorhexidine mouthrinse for oral mucositis in patients undergoing allo-hsct

Conditions: Stem Cell Transplant Complications; Oral Mucositis

Summary: oral mucositis (om) is a common complication in patients receiving myeloablative conditioning allogeneic hematopoietic stem cell transplantation (allo-hsct). chlorhexidine mouthrinse offers a cost-effective prophylactic approach to preventing om, yet its use is hampered by issues like tooth discoloration, unpleasant taste, and pain on ulcerated surfaces, leading to reduced patient compliance. this study aims to demonstrate the non-inferior efficacy of a compound staphylococcal lysostaphin mouthrinse to that of chlorhexidine mouthrinse in reducing om occurrence in patients receiving myeloablative conditioning allo-hsct.

this study aims to demonstrate the non-inferior efficacy of a compound staphylococcal lysostaphin mouthrinse (xinjingjie mouthrinse®) to that of chlorhexidine mouthrinse in reducing om occurrence in patients receiving myeloablative conditioning allo-hsct. it also seeks to observe patient treatment adherence and pain, so as to provide evidence for the appropriate om prevention and management measures in clinical practice. this randomized, controlled, non-inferiority clinical trial was conducted at the bone marrow transplant center, the first affiliated hospital of medical college, zhejiang university from january 2020 to december 2021.

Eligibility criteria:
inclusion criteria: * patients with malignant hematological diseases who are undergoing allogeneic hematopoietic stem cell transplantation (hsct) from fully matched sibling donors, unrelated donors, or haploidentical related donors. * the conditioning regimen is myeloablative, specifically the bucy regimen (comprising cytarabine, busulfan, and cyclophosphamide), with methotrexate used for graft-versus-host disease (gvhd) prophylaxis. the dosage of cytarabine is ≥4.0g/m²/day, busulfan is ≥3.2mg/m²/day, and cyclophosphamide is ≥1.8g/m²/day. * there are no restrictions on age or gender. * patients voluntarily agree to participate in this trial. exclusion criteria: * patients with an expected survival time of less than one month; * patients who have already developed oral mucositis (om) prior to conditioning; * patients undergoing autologous stem cell transplantation; * patients receiving a non-myeloablative conditioning regimen.